Linifanib

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis[1][2].

Product Specifications

CAS Number

[796967-16-3]

Product Name Alternative

ABT-869; AL-39324

UNSPSC

12352005

Hazard Statement

H361, H372, H410

Target

Apoptosis; Autophagy; c-Fms; c-Kit; FLT3; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/linifanib.html

Purity

99.72

Solubility

DMSO : 13.16 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(C2=C3C(N)=NNC3=CC=C2)C=C1)NC4=C(C=CC(C)=C4)F

Molecular Formula

C21H18FN5O

Molecular Weight

375.40

Precautions

H361, H372, H410

References & Citations

[1]Albert DH, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther, 2006, 5 (4), 995-1006.|[2]Monroig-Bosque PDC, et al. OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep. 2018;8 (1) :13106. Published 2018 Aug 30.|[3]Banchi M, et al. Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer. Am J Cancer Res. 2020;10 (7) :2120-2127. Published 2020 Jul 1.